Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-p6h7k Total loading time: 0.813 Render date: 2022-05-22T10:21:19.275Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

8 - Fluphenazine and Fluphenazine Decanoate

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

As with many first-generation antipsychotics (FGAs), fluphenazine has no unique therapeutic benefit compared to other D2 antagonists, but does have multiple formulations including a long-acting injectable (LAI), and an extensive database of plasma level information [1–2, 5–12]. The cytochrome P450 pathways and effects of inhibitors and inducers are less well studied than for other FGAs, and there are fewer studies on oral dose–concentration relationships which account for confounding issues such as smoking [3].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 174 - 189
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dysken, M. W., Javaid, J. I., Chang, S. S., et al. (1981). Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berl), 73, 205210.
Levinson, D. F., Simpson, G. M., Lo, E. S., et al. (1995). Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry, 152, 765771.
Ereshefsky, L., Jann, M. W., Saklad, S. R., et al. (1985). Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry, 20, 329332.
Koreen, A. R., Lieberman, J., Alvir, J., et al. (1994). Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. Am J Psychiatry, 151, 3539.
Marder, S. R., Midha, K. K., Van Putten, T., et al. (1991). Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: Relationship to clinical response. Br J Psychiatry, 158, 658665.
Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254264.
Jann, M. W., Ereshefsky, L., and Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet, 10, 315333.
Marder, S. R., Van Putten, T., Aravagiri, M., et al. (1989). Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. Psychopharmacol Bull, 25, 479482.
Van Putten, T., Marder, S. R., Wirshing, W. C., et al. (1991). Neuroleptic plasma levels. Schizophr Bull, 17, 197216.
Miller, R. S., Peterson, G. M., McLean, S., et al. (1995). Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther, 20, 5562.
Gitlin, M. J., Nuechterlein, K. H., Mintz, J., et al. (2000). Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression. Psychopharmacology, 148, 350354.
Marder, S. R., Aravagiri, M., Wirshing, W. C., et al. (2002). Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res, 53, 2530.
Van Putten, T., Aravagiri, M., Marder, S. R., et al. (1991). Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharmacol Bull, 27, 9196.
Coppens, H. J., Slooff, C. J., Paans, A. M., et al. (1991). High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry, 29, 629634.
Nyberg, S., Dencker, S. J., Malm, U., et al. (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol, 1, 95101.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi/10.4088/JCP.4019cs13169.
Midha, K. K., Hawes, E. M., Hubbard, J. W., et al. (1988). Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology (Berl), 96, 206211.
Koytchev, R., Alken, R. G., McKay, G., et al. (1996). Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol, 51, 183187.
Aravagiri, M., Marder, S. R., Yuwiler, A., et al. (1995). Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology, 13, 235247.
Goff, D. C., Midha, K. K., Sarid-Segal, O., et al. (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl), 117, 417423.
Jann, M. W., Fidone, G. S., Hernandez, J. M., et al. (1989). Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res, 28, 153159.
Coffman, J. A., Nasrallah, H. A., Lyskowski, J., et al. (1987). Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry, 48, 2024.
Harasko-van der Meer, C., Brucke, T., Wenger, S., et al. (1993). Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm, 94, 217221.
Carpenter, W. T., Jr., Buchanan, R. W., Kirkpatrick, B., et al. (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry, 156, 412418.
Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. Br J Psychiatry Suppl, 52, S1319.
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279302.
Ereshefsky, L., Saklad, S. R., Jann, M. W., et al. (1984). Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry, 45, 5059.
Bristol-Myers Squibb Company (2017). Modecate Concentrate (Fluphenazine Decanoate injection, BP 100 mg/ml) product monograph. Montreal, Canada.
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.
Ereshefsky, L. and Mascarenas, C. A. (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry, 64, 1823.
Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: A guide for the perplexed. CNS Spectr, 22, 1428.
Glazer, W. M. (1988). Fluphenazine decanoate: Its steady-state pharmacologic profile and relationship to tardive dyskinesia. Schizophr Res, 1, 425429.
Heresco-Levy, U., Greenberg, D., Lerer, B., et al. (1997). Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy. Isr J Psychiatry Relat Sci, 34, 281289.
Baldelli, S., Clementi, E., and Cattaneo, D. (2018). Can we rely on AGNP therapeutic targets also for LAI antipsychotics? Pharmacopsychiatry, 51, 270271.
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318325.
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr, 19, 432438.
Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136144.
Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269274.
Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789796.
Kapur, S. and Seeman, P. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry, 158, 360369.
Sparshatt, A., Taylor, D., Patel, M. X., et al. (2010). A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J Clin Psychiatry, 71, 14471556.
Seneca, N., Finnema, S. J., Laszlovszky, I., et al. (2011). Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl), 218, 579587.
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol, 31, 497502.
Lim, H. S., Kim, S. J., Noh, Y. H., et al. (2013). Exploration of optimal dosing regimens of haloperidol, a D2 antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Pharm Res, 30, 683693.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×